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Abstract
Background: RNA from exosomes and other microvesicles contain transcripts of tumour origin. In this study we
sought to identify biomarkers of glioblastoma multiforme in microvesicle RNA from serum of affected patients.
Methods: Microvesicle RNA from serum from patients with de-novo primary glioblastoma multiforme (N = 9) and
normal controls (N = 7) were analyzed by microarray analysis. Samples were collected according to protocols
approved by the Institutional Review Board. Differential expressions were validated by qRT-PCR in a separate set of
samples (N = 10 in both groups).
Results: Expression profiles of microvesicle RNA correctly separated individuals in two groups by unsupervised
clustering. The most significant differences pertained to down-regulated genes (121 genes > 2-fold down) in the
glioblastoma multiforme patient microvesicle RNA, validated by qRT-PCR on several genes. Overall, yields of
microvesicle RNA from patients was higher than from normal controls, but the additional RNA was primarily of size
< 500 nt. Gene ontology of the down-regulated genes indicated these are coding for ribosomal proteins and
genes related to ribosome production.
Conclusions: Serum microvesicle RNA from patients with glioblastoma multiforme has significantly down-
regulated levels of RNAs coding for ribosome production, compared to normal healthy controls, but a large
overabundance of RNA of unknown origin with size < 500 nt.
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Background
Cancer molecular diagnostics is becoming increasingly
important with the accumulating knowledge of the
molecular mechanisms underlying various types of can-
cers and the implications for treatment option selection
and prognosis. For patients with glioblastoma multi-
forme (GBM), treatment planning currently takes into
account radiographic imaging, which documents volume
and location of disease [1], and in some cases muta-
tional analysis [2], methylation status of genomic DNA
with particular emphasis on the DNA repair gene for
methyl guanidine methyl transferase (MGMT [3]) and
gene expression patterns of the tumour, which allows
the broad categorization of tumours that are histologi-
cally similar into molecular subtypes [4]. To date most
molecular studies have utilized primary explant cultures
or frozen, formalin fixed tumour tissue derived at the
time of surgical resection. These methods have the dis-
advantage that the part of the tumour specimen chosen
for analysis may not represent the rest of the tumour,
and the molecular profile of the recurrent tumour may
be very different from the original biopsy. It would be
very useful to have a way to monitor and evaluate the
tumour gene expression pattern over time in a non-
invasive assay, such as through a blood sample test.
Over the past few years a growing list of studies has
reported on the ability to use expression profiling tests
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between healthy controls and patients with certain types
of cancer [5-8], to classify separate patient populations
[9] or to predict clinical outcome [10]. The ability to
conduct nucleic acid expression profiling assays on a
blood sample rather than on tumours has a wide range
of implications for patient welfare, including the ability
to conduct longitudinal disease monitoring in situations
w h e r et u m o u rt i s s u ei sn o te a s i l ya c c e s s i b l eo ro n ei s
trying to sample metastatic cancer. Because the blood
harbors nucleic acid of both tumour and non-tumour
origin, it is possible that this approach may capture not
only direct nucleic acid changes seen in the tumour
cells, but also a component of the host response to the
presence of tumour. For example, studies so far have
reported on RNA extracted from Peripheral Blood
Mononuclear Cells (PBMC) or other fractions of circu-
lating blood cells where changes in the cell RNA profile
appears to represent the host’sr e s p o n s et ot h em a l i g -
nancy [5] rather than the tumour itself. Different groups
have isolated RNA from circulating tumour cells [11]
and from cell-free body fluids [12]. Given the short half-
life of unprotected RNA in serum [13], it is likely that
most of the cell-free RNA is protected in the exosomes/
microvesicle fraction or in the case of microRNAs (miR-
NAs) by protein complexes in the blood [14,15].
Microvesicles are very stable and can protect cell-free
RNA stored in the freezer for many years. This is a great
advantage compared to analyzing circulating tumour
cells where the blood needs to be processed within hours
of collection. In addition, circulating tumour cells have
not yet been described in glioma patients [16]. In this
study, full microarray analysis was carried out on mRNA
isolated from serum microvesicles (including exosomes
and other shedding microvesicles [17]) from GBM
patients and controls to test the hypothesis that this
mRNA could be used to reflect tumour-associated
changes in the exosomal/microvesicle fraction of serum
RNA. RNA species showing differential expression were
chosen for quantitative reverse transcriptase (qRT-PCR)
validation. This study is the first to report the ability to
differentiate GBM patients from normal controls based
on a gene expression blood test and the first to report
differential expression analysis using RNA extracted from
exosomes/microvesicles isolated from clinical patient
serum samples, as compared to controls.
Methods
Clinical samples
Blood samples from patients diagnosed with de-novo pri-
mary GBM were collected immediately prior to surgery
(before opening of the dura mater) into a BD Vacutainer
SST (#367985) at Massachusetts General Hospital
(MGH). Patients were following standard of care at
MGH, including fasting prior to surgery and most of the
patients were treated with steroids to alleviate vasogenic
edema and pain. Blood from normal healthy controls was
collected from de-identified volunteers recruited at the
MGH blood bank. All samples were collected with
informed consent according to the appropriate protocols
approved by the Institutional Review Board at MGH. The
blood was left to clot for 30 min at room temperature (r.
t.) and serum was isolated, according to manufacturer’s
recommendations within 2 h of collection. Serum was fil-
t e r e db ys l o w l yp a s s i n gi tt h r o u g ha0 . 8μm syringe filter
(Millopore, Billerica, MA, USA) and aliquoted into 1.8
mL cryotubes (Fisher Scientific, Waltham, MA, USA)
and stored at -80°C until use.
Isolation of microvesicle RNA
Isolation of RNA from microvesicles was performed as
previously described [18] with a few modifications.
Briefly, 1 mL of serum was transferred to an ultracentri-
fuge tube, diluted 1:3 with cold PBS and centrifuged at
120,000 g for 80 min at 8°C and the supernatant was
carefully aspirated off without disturbing the microvesi-
cle pellet. The pellet was resuspended, treated for 15
min with 4 U of DNase I (Ambion, Austin, TX, USA)
(in 25 μL of the accompanying buffer), 700 μLm i R -
Neasy lysis buffer (Qiazol Reagent) (Qiagen, Valencia,
CA, USA) was then added to the tube and the RNA was
isolated following the manufacturer’s recommendations.
After elution of the RNA from the column in 30 μL
nuclease-free water (Ambion), the RNA was precipitated
by adding 2.5 volumes 100% EtOH, 1/10 3 M sodium
acetate (pH 5.2) and incubated at -20°C for 1 h. Samples
were then centrifuged for 20 min at 16,000 g and the
supernatant was removed. The pellet was left to dry at
r.t. and dissolved in 14 μL nuclease-free water and
stored at -80°C until needed. RNA quality and concen-
tration was assessed with the Agilent Bioanalyzer RNA
Pico Chip and the Nanodrop 2000 (Thermo Scientific,
Wilmington, DE, USA).
Linear amplification and array hybridization
Linear amplification and hybridization to Agilent micro-
arrays was carried out by Miltenyi, according to manu-
facturer’s recommendations. Briefly, exoRNA was
linearly amplified and fluorescently labeled with Cy3
using Low Input Quick Amp Labeling Kit (Agilent,
Santa Clara, CA, USA) and 1.4 μg amplified RNA was
hybridized to Agilent 4×44K Human Microarrays,
washed and scanned. Raw data was generated by image
analysis using Feature Extraction (Agilent).
Microarray data analysis
The raw data exported from Agilent Feature Extraction
v9.1 was pre-processed and normalized using R/
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cess and vsn (see R script in the Additional file 1 infor-
mation for details). Where not mentioned in the text,
the data from quartile normalization after background
subtraction were used.
To reduce the risk that the normalization procedure
introduced unintended biases or artifacts, we normalized
the data in three different ways using: 1) variance stabi-
lized normalization (VSN); 2) quartile normalization
with background subtraction; and 3) quartile normaliza-
tion without background subtraction. Although there
were small differences between the three methods many
of the same genes turned out to be dysregulated regard-
less of the applied normalization.
Clustering analysis, heat maps and Linear Discrimi-
nant Analysis of the normalized data was done using
dChip (http://biosun1.harvard.edu/complab/dchip). Nor-
malized data was transferred to Excel and filtered with
various criteria, as described in the text. Gene lists of
interest were uploaded and analyzed with the online
Gene Ontology Tool DAVID 6.7 http://david.abcc.
ncifcrf.gov/. The raw data and the quartile normalized
mean data with background subtraction has been depos-
ited in GEO with accession# GSE24084.
Reverse transcription and qPCR analysis
Twelve μL of the RNA isolated from 1 mL of serum
were reverse transcribed using Superscript VILO cDNA
synthesis kit (Invitrogen, Carlsbad, CA, USA), according
to manufacturer’s recommendations. Samples were then
preamplified using the TaqMan
® PreAmp Master Mix
(Applied Biosystems, Carlsbad, CA, USA). Briefly, 12.5
μL of the cDNA was added to the PreAmp Master Mix
together with all the genes of interest and pre- amplified
for 14 cycles, according to the manufacturer’sr e c o m -
mendations. The samples were then diluted 1:10 and
TaqMan qRT-PCR was performed on all samples for all
the selected genes. The amplification was performed
using ABI PRISM 7500 with the following program: 50°
C, 2 min; 95°C, 10 min; 40 cycles of 95°C, 15 s, 60°C, 1
min on standard mode. Additional file 2: Table S1 con-
tains a list of all the commercially available and custom
made probes used.
Results
Unsupervised clustering separates GBM patients from
controls in expression array analysis
Exosomes and other microvesicles (less than 0.8 μmi n
diameter, see methods) were isolated from serum sam-
ples from 9 GBM patients immediately prior to tumour
removal and from 7 normal healthy controls. RNA from
this microvesicle fraction (exoRNA) was extracted,
amplified by linear amplification, labeled and hybridized
to Agilent microarrays containing 44,000 (44 K) capture
probes against essentially all genes in the human gen-
ome. The raw data was background corrected and nor-
malized between samples, as described in the Methods
section. To investigate whether the two sets of samples
could be separated by unsupervised clustering (without
prior knowledge of the identity of each sample), we fil-
tered the data to only include probes for which at least
4 out of 16 samples had a high signal intensity (intensity
> 6) and for which the variation across all samples was
high (Std. dev. > 0.8). This approach effectively excluded
probes that displayed constant intensity in all samples
and therefore did not contribute to distinguishing
between the two groups. The selected subset of 206
probes thus displayed both variation and intensity,
which are prerequisites for contributing to discrimina-
tion between the two groups. When the signal from
these probes was analyzed with unsupervised clustering
it perfectly separated the GBMs from the controls as
illustrated by the heat map and dendrogram in Figure
1A. The sample dendrogram at the top of the heat map
has two primary branches illustrating the perfect separa-
tion the GBM samples from the Normal Controls. The
gene dendrogram to the left of the heat map separates
the genes that are up-regulated from those that are
down-regulated in GBM samples, respectively. The
observation that the data clustered perfectly into two
distinct groups without any pre-selection of genes based
on t-test analysis indicates that there are significant dif-
ferences in the expression profiles of the GBM exoRNA
and the normal control exoRNA, even though the
Figure 1 A total of 206 genes were selected without
application of t-test by filtering for high signal intensity (> 6 in
30% of samples) and high variation between samples (stdev >
0.8 across all 16 samples). A) A heat map and dendrogram
showing perfect unsupervised clustering of the samples based on
these 206 genes. B) Principal Component Analysis (PCA) of the
same 206 genes as in A.
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mal power calculation criteria [19].
With the observation of differences between GBM and
control RNA expression patterns, we sought to identify
the genes that best separated the two groups by con-
ducting gene-by-gene t-tests between the groups on all
genes in the full 44 K data set and corrected the result-
ing p-values for False Discovery Rate (FDR) by applying
the Benjamini and Hochberg algorithm [20]. The 25
most down- and up-regulated genes are listed in Table
1 and more extensive lists of the 200 most down- and
up-regulated genes are available in Additional file 2:
Table S2 and Table S3, respectively. From the top den-
drogram in Figure 1A, which was prepared without the
use of p-values, it would appear that the GBM samples
separate into two distinct sub-groups. However, when
we performed a gene-by-gene t-test between these two
apparent groups of GBM samples no significant genes
were left that met the p < 0.05 criteria for statistical sig-
nificance after application of Benjamini and Hochberg
correction for FDR. Similarly, when the genes in Addi-
tional file 2: Table S2 and Table S3 were used together
for cluster analysis, there was a clear separation of
GBMs from controls as seen in Figure 2, but the two
distinct groups of GBM samples were no longer appar-
ent. From Figure 3, which shows a volcano plot of the
FDR corrected p-values against the level of differential
expression for each gene, it is evident that substantially
more genes were found to be significantly down-regu-
lated (121 genes) than up-regulated (24 genes) in the
GBM samples compared to controls.
Gene ontology analysis
Normalization of array data can be done in a number of
different ways, each having its own advantages and dis-
advantages. To reduce the risk that the normalization
procedure introduced unintended biases or artifacts, we
normalized the data in three different ways, as described
in Methods. For gene ontology analysis we used the top
two hundred genes that passed the criteria p <0 . 0 5
after FDR-correction in all three normalization proce-
dures mentioned above (Additional file 2: Table S2 and
Table S3). All genes listed in the tables of this paper
met the same selection criteria.
Down-regulated genes in serum microvesicles from GBM
patients
We analyzed the up- and down-regulated genes inde-
pendently to try to identify brain- or GBM-specific
genes up-regulated in the GBM patients due to the
microvesicle shedding activity of the tumour, as well as
genes down-regulated in normal cells, such as platelets,
lymphocytes and endothelial cells [21] that also shed
microvesicles into the blood. Gene ontology analysis of
the 200 most down-regulated genes (from -4.21 to
-1.92-fold, Additional file 2: Table S2) using the online
tool, DAVID [22] revealed that an overwhelming major-
ity of the resulting GO terms are related to ribosome
functions, e.g. “Ribosome”, “Translational Elongation”
and “RNA Binding”. The most significant cluster had an
enrichment score of 54.82 and contained 115 of the 200
input genes, most of which were mRNAs coding for
ribosomal proteins in both the large and small subunits
of the ribosome (e.g. RPL11, RPS29, RPLP1, RPS27A,
etc.). These genes have previously been shown to be
very highly expressed in lymphocytes relative to other
blood cells [23,24]. Evaluation of the percentage of lym-
phocytes in the white blood cell (WBC) counts in the
G B Mp a t i e n t su s e di nt h i ss t u d y ,s h o w e dt h a t7o u to f
the 9 patients used for array analysis and 9 out of the
10 patients used for qPCR validation had values of 3-
19% lymphocytes, which is well below the reference
interval for normal healthy individuals of 22-28% [25]
and is consistent with immunosuppression observed in
most GBM patients [26]. Unfortunately, the de-identi-
fied normal control samples used for this study were
obtained through a blood bank so no detailed informa-
tion is available on their blood cell counts.
Up-regulated genes in microvesicles from GBM patients
When we left out the down-regulated genes and
attempted unsupervised clustering using only genes that
were up-regulated in microvesicles from GBM patients
(Table 1/Additional file 2: Table S3), no clear separation
of the GBMs from the normal controls was evident.
Further, gene ontology analysis of the up-regulated
genes in Table 1/Additional file 2: Table S3 resulted in
clusters and GO terms with enrichment scores substan-
tially lower (< 3) than for the down-regulated genes in
Table 1/Additional file 2: Table S2 (> 50).
Validation analysis by qRT-PCR
We moved on to see if some of the dysregulated genes
from the microarray could be validated as dysregulated
by qRT-PCR in an independent set of 10 patients and
10 controls. We selected individual up-regulated genes
from the lists in Table 1/Additional file 2: Table S3 in
search of markers associated with GBM tumours. We
sought to identify mRNAs up-regulated in the microve-
sicles in peripheral blood from GBM patients, which
were expressed at low to undetectable levels in blood
cells, and elevated in either GBM or normal brain cells.
We reasoned that since the majority of microvesicles in
blood are believed to arise from platelets [27] and other
blood cells, the RNA expression of these cells could
serve as an approximation of the normal blood microve-
sicle RNA profile. We compared public datasets in Gene
Expression Omnibus (GEO) for GBM (GSE15824) to
Noerholm et al. BMC Cancer 2012, 12:22
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Page 4 of 11Table 1 Down-and up-regulated genes passing the criteria described in “Results”
Down-regulated genes
No Gene Symbol Fold Description
1 TMSL3 -4.21 Homo sapiens thymosin-like 3 (TMSL3), mRNA [NM_183049]
2 A_24_P530977 -4.00 Unknown
3 GNG11 -3.86 Homo sapiens guanine nucleotide binding protein (G protein), gamma 11 (GNG11), mRNA [NM_004126]
4 RPS4Y2 -3.80 Homo sapiens ribosomal protein S4, Y-linked 2 (RPS4Y2), mRNA [NM_001039567]
5 RGS10 -3.63 Homo sapiens regulator of G-protein signalling 10 (RGS10), transcript variant 1, mRNA [NM_001005339]
6 RPS4Y1 -3.62 Homo sapiens ribosomal protein S4, Y-linked 1 (RPS4Y1), mRNA [NM_001008]
7 B2M -3.60 Homo sapiens beta-2-microglobulin (B2M), mRNA [NM_004048]
8 CCL5 -3.35 Homo sapiens chemokine (C-C motif) ligand 5 (CCL5), mRNA [NM_002985]
9 AL049447 -3.35 Homo sapiens mRNA; cDNA DKFZp586A0722 (from clone DKFZp586A0722). [AL049447]
10 GPX1 -3.27 Homo sapiens glutathione peroxidase 1 (GPX1), transcript variant 2, mRNA [NM_201397]
11 RPS29 -3.12 Homo sapiens ribosomal protein S29 (RPS29), transcript variant 1, mRNA [NM_001032]
12 IER2 -3.12 Homo sapiens immediate early response 2 (IER2), mRNA [NM_004907]
13 RAP1B -2.94 Homo sapiens RAP1B, member of RAS oncogene family (RAP1B), transcript variant 1, mRNA [NM_015646]
14 MMD -2.93 Homo sapiens monocyte to macrophage differentiation-associated (MMD), mRNA [NM_012329]
15 MAX -2.89 Homo sapiens MYC associated factor × (MAX), transcript variant 3, mRNA [NM_145113]
16 TMEM111 -2.87 Homo sapiens transmembrane protein 111 (TMEM111), mRNA [NM_018447]
17 RPS29 -2.82 Homo sapiens ribosomal protein S29 (RPS29), transcript variant 1, mRNA [NM_001032]
18 RPL19 -2.81 Homo sapiens ribosomal protein L19 (RPL19), mRNA [NM_000981]
19 RPL13 -2.80 Homo sapiens ribosomal protein L13 (RPL13), transcript variant 2, mRNA [NM_033251]
20 LOC392497 -2.78 PREDICTED: Homo sapiens similar to 40S ribosomal protein S6 (LOC392497), mRNA [XR_018138]
21 MRCL3 -2.74 Homo sapiens myosin regulatory light chain MRCL3 (MRCL3), mRNA [NM_006471]
22 RPL30 -2.72 Homo sapiens ribosomal protein L30 (RPL30), mRNA [NM_000989]
23 RPS27 -2.70 Homo sapiens ribosomal protein S27 (metallopanstimulin 1) (RPS27), mRNA [NM_001030]
24 ENST00000337102 -2.70 40S ribosomal protein S21. [Source:Uniprot/SWISSPROT;Acc:P63220] [ENST00000337102]
25 RPA1 -2.68 Homo sapiens replication protein A1, 70 kDa (RPA1), mRNA [NM_002945]
Up-regulated genes
No Gene Symbol Fold Description
1 CV575560 3.80 oe37f10.y1 Human keratoconus cornea, unamplified, od [CV575560]
2 RKHD1 2.32 Homo sapiens ring finger and KH domain containing 1 (RKHD1), mRNA [NM_203304]
3 ZNF784 2.65 Homo sapiens zinc finger protein 784 (ZNF784), mRNA [NM_203374]
4 SERPINB1 2.62 Leukocyte elastase inhibitor (LEI) (Serpin B1) (Monocyte/neutrophil elastase inhibitor) (M/NEI) (EI).
5 LOC390427 2.00 PREDICTED: Homo sapiens similar to TBP-associated factor 15 isoform 1 (LOC390427), mRNA [XM_372498]
6 FOXD3 2.32 Homo sapiens forkhead box D3 (FOXD3), mRNA [NM_012183]
7 C17orf74 1.97 Homo sapiens chromosome 17 open reading frame 74 (C17orf74), mRNA [NM_175734]
8 ENST00000357697 1.67 Unknown
9 SLITRK4 2.30 Homo sapiens SLIT and NTRK-like family, member 4 (SLITRK4), mRNA [NM_173078]
10 AGRP 2.03 Homo sapiens agouti related protein homolog (mouse) (AGRP), transcript variant 1, mRNA [NM_001138]
11 ENST00000359466 1.77 chromosome × open reading frame 18 (CXorf18), misc RNA [RefSeq_dna;Acc:XR_018001] [ENST00000359466]
12 THC2760960 1.41 Unknown
13 TNXB 2.06 Homo sapiens tenascin XB (TNXB), transcript variant XB, mRNA [NM_019105]
14 THC2755576 1.90 ALU1_HUMAN (P39188) Alu subfamily J sequence contamination warning entry, partial (13%) [THC2755576]
15 SIN3B 1.60 Homo sapiens SIN3 homolog B, transcription regulator (yeast), complete cds. [BC063531]
16 CRLF1 1.66 Homo sapiens cytokine receptor-like factor 1 (CRLF1), mRNA [NM_004750]
17 ZNF219 1.97 Homo sapiens zinc finger protein 219 (ZNF219), mRNA [NM_016423]
18 THC2654039 1.78 ALU2_HUMAN (P39189) Alu subfamily SB sequence contamination warning entry, partial (4%) [THC2654039]
19 AA418814 1.59 AA418814 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3’, mRNA sequence [AA418814]
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from normal controls to derive a list of “GBM-like”
genes highly expressed in GBM, but low or absent in
platelets and PBMCs and similarly a list of “blood cell-
like” genes highly expressed in platelets and PBMCs.
When we compared the “GBM-like” genes to the genes
f o u n dt ob eu p - r e g u l a t e di nG B Mp a t i e n tb l o o dm i c r o -
vesicle RNA in our own dataset, we found no overlap to
support GBM tumour origin of these RNAs. On the
other hand, many of the “blood cell-like” genes were the
same as those found in our study to be down-regulated
in GBM patients relative to normal controls (data not
shown).
In selecting genes for further qPCR validation we also
considered whether genes were represented in the GO
clusters and whether they were genes previously deter-
mined to have cancer association. The following genes
were chosen for validation studies by qRT-PCR: RPL11,
RPS12, TMSL3 and B2M as expected down-regulated
genes and EGFR, ERBB2, SLITRK4, HOXA4, METT5D1,
CV575560, TNXB, ALUY, 7SL and THC2718728 as pos-
sible up-regulated genes. For normalization of the qRT-
PCR data we chose GAPDH, which appeared to be
stable in our exoRNA samples judging from the array
data, as well as 18S rRNA. The qRT-PCR validation was
performed on a different set of GBM patients (N = 10)
and controls (N = 10) than the array data. We were able
to confirm the down-regulation of genes associated with
ribosome production RPL11, RPS12, TMSL3 and B2M
observed in the arrays as illustrated in Figure 4, but the
expected up-regulated genes did not show any signifi-
cant increase relative to controls by qRT-PCR (data not
shown). RNA was extracted from equal volumes of
serum (1 mL) from GBM patients and normal controls.
The exoRNA content of the GBM patient serum sam-
ples used for qRT-PCR validation in this study, (30.0 +/-
8.3 ng/mL serum; N = 10) was significantly higher (p <
0.001) than in the normal control serum samples (8.8
+/- 2.2 ng/mL serum; N = 10). For the microarray
Table 1 Down-and up-regulated genes passing the criteria described in ?“?Results?”? (Continued)
20 TNRC4 1.72 Homo sapiens trinucleotide repeat containing 4 (TNRC4), mRNA [NM_007185]
21 AK098372 1.94 Homo sapiens cDNA FLJ25506 fis, clone CBR05185. [AK098372]
22 TNRC6B 1.79 Homo sapiens trinucleotide repeat containing 6B (TNRC6B), transcript variant 1, mRNA [NM_015088]
23 HOXA4 1.58 Homo sapiens homeobox A4 (HOXA4), mRNA [NM_002141]
24 IL26 1.66 Homo sapiens interleukin 26 (IL26), mRNA [NM_018402]
25 THC2718728 1.73 Unknown
“Fold” is calculated as the median value of the fold change in the three described normalization procedures
Figure 2 Analysis of the 400 most dysregulated genes. The 200
most down- and up-regulated genes, respectively, with p < 0.05 in
all three normalizations after correction for False Discovery Rate
were used (see Additional file 2: Table S1 and Table S2). A) Cluster
analysis, B) PCA plot.
Figure 3 Volcano plot of the False Discovery Rate (FDR)
corrected p-values from a t-test between the two sample
groups after background subtraction and quartile
normalization. Genes above the horizontal dashed line have p <
0.05 after FDR correction. It is evident that substantially more genes
are significantly down-regulated (121 genes in upper left corner, >
2-fold) than up-regulated (24 genes in upper right corner, > 2-fold).
Noerholm et al. BMC Cancer 2012, 12:22
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amount of RNA was hybridized to all arrays. For the
qRT-PCR, the data was normalized to the house-keeping
genes GAPDH and 18S. Interestingly, when the qRT-
PCR data was normalized to the amount of RNA in the
sample all genes initially found to be up-regulated by
array analysis appeared to be down-regulated in serum
microvesicles from GBM patients, as compared to nor-
mal controls (Figure 5A). Inspection of the bioanalyzer
profiles of the RNA samples used in this study sug-
gested that the major contribution of the increased
RNA amounts seemed to stem from a larger peak of
small RNA migrating in the range from 25-300 nt on
the bioanalyzer RNA chip (Figure 5B).
Discussion
Our findings demonstrate the feasibility of genome wide
gene expression analysis of RNA extracted from the
cell-free microvesicle fracti o n( e x o R N A )o ff r o z e nb i o -
banked serum samples, and that clear differences can be
observed between the exoRNA expression profiles from
GBM patients and normal controls. The two major dif-
ferences between exoRNA from GBM patients vs. nor-
mal controls were found to be: 1) a significantly reduced
level of mRNAs encoding ribosomal protein genes; and
2) an overall significant up-regulation of RNA amounts
in the serum of GBM patients, which seems to be pri-
marily due to a larger fraction < 300 nt and could not
be attributed to any of the mRNAs investigated by qRT-
PCR.
ExoRNA from tumour microvesicles in serum will
always be diluted into the background of exoRNA com-
ing from normal non-malignant cells. Depending on the
purpose of the study, normal exoRNA may also generate
useful information. Previous studies have indicated that
RNA expression patterns in blood cells can change as a
response to tumours [7]. To look specifically at the
genes dysregulated in the tumour, one would need to
enrich the tumour specific microvesicle fraction before
extracting the RNA.
Microvesicles are shed by many different cell types
into the blood stream, including circulating WBCs, pla-
telets, endothelial cells, and dendritic cells [17]. Shed-
ding has been shown to be higher from tumour cells in
culture compared to normal fibroblasts [28] and
tumour-derived microvesicle concentrations in serum
increase as a function of increased malignancy [29,30].
However, microvesicles of tumour origin circulating in
the blood are mixed with microvesicles from other cell
Figure 4 Validation by qRT-PCR of down-regulated genes. Gene
expression levels were normalized to the combined expression of
GAPDH and 18S. Lines represent median values for the GBM and
control samples, respectively.
Figure 5 Serum microvesicle RNA from patients with glioblastoma multiforme has an overabundance of RNA with size <500 nt.( A )
Gene expression relative to the amount of microvesicle RNA present in serum of GBM patients and normal healthy controls. Bars represent the
average expression of 16 genes as measured by qRT-PCR, normalized to the amount of exoRNA isolated from 1 mL of serum. The yield from
GBM samples is higher than from controls, but this does not result in higher gene expression. (B) From the Bioanalyzer profiles it appears that
the extra RNA in GBM serum is predominantly <300 nt. The plot is showing the mean ± SEM (N = 10 GBM and 10 controls). The non-visible
parts of the profiles (>500 nt) were very similar for GBM and controls
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Page 7 of 11sources and it is likely that tumour microvesicles in
many cases constitute a relatively small fraction of the
total population.
There is a large contribution of microvesicles from
normal cells and platelets in blood. In control plasma,
for example, platelet-derived microvesicles have been
reported to constitute the majority of all microvesicles
[27] and although tumour-derived microvesicles increase
in serum as a function of degree of malignancy in ovar-
ian cancer [30] and that the total number of microvesi-
cles in blood increase with disease progression [29], it is
not clear what proportion of the increased number of
vesicles is coming from the tumour vs. from normal
cells as a response to the tumour. Thus, down-regulated
genes in GBM exoRNA could either be caused by
altered biological processes in normal cells as a response
to or consequence of the disease, or by large numbers of
tumour microvesicles with low levels of particular
RNAs.
A major fraction of the genes we observed to be sig-
nificantly down-regulated in serum microvesicles from
GBM patients in this study code for various ribosomal
proteins (e.g. RPL11, RPS29, RPLP1, RPS27A,e t c . ) .
However, these genes were not found to be among the
most abundant transcripts in platelets in a study by [31],
which we also confirmed in our analysis of the public
dataset from GEO (GSE11524). We speculate that these
R N A sw o u l dt h e r e f o r ea l s on o tb ea b u n d a n ti nt h ep l a -
telet-derived microvesicles, which constitute a substan-
tial fraction of the plasma microvesicles [27]. However,
these genes have been shown to be very highly
expressed in lymphocytes relative to other blood cells
[23,24] and were also found to be up-regulated in our
analysis of the public dataset for PBMC (GSE22224)
relative to GBM. This led us to speculate that the lower
abundance of these mRNAs in circulating microvesicles
from GBM patients may be a consequence of a reduced
level of lymphocyte-derived microvesicles in patients as
compared to normal controls, since cancer patients are
known to often be immune-compromised [26]. Evalua-
tion of the GBM patients in this study confirmed that
their lymphocyte counts were lower than the normal
reference level interval, but because we were unable to
measure lymphocyte counts in the normal controls, it is
impossible to completely correlate transcript down-regu-
lation with lymphocyte depletion in the GBM patients.
None of the GBM patients had received chemotherapy
prior to diagnosis, but several of them were on steroids
and seizure medications at the time of blood draw,
which are two potential sources of lymphocytopenia.
Evaluation of gene expression differences between lym-
phocytopenia caused by cancer and by medication
would require a much larger study of more carefully
chosen subjects.
The observation that many ribosomal protein genes
are down-regulated in GBM serum microvesicles may
prove to be a valuable contributory marker for GBM
and other pathological states. Sharma et al. [5] also
observed a reduction in many of the same genes in
PBMCs including lymphocytes, from breast cancer
patients compared to normal controls. The down-regu-
lation of ribosomal protein genes is therefore unlikely to
provide a specific GBM component for a diagnostic
classification, but may serve as a more generic patholo-
gical indicator and can provide confirmatory support
when combined with other exoRNA profiles. Interest-
ingly, many ribosomal proteins have extra-ribosomal
functions that go beyond the function of protein bio-
synthesis. Ribosomal protein genes have been shown to
have important regulatory functions also in cancer cells.
Some ribosomal proteins are tumour suppressors [32],
oncogenes or have regulatory functions in tumour pro-
gression, invasion and metastasis [33].
The “ribosome” GO-clusters from down-regulated genes
had very high enrichment scores from DAVID (> 50)
compared to any of the clusters obtained with up-regu-
lated genes (< 2.5), confirming that the patterns of down-
regulated genes were much more significant. For gene
ontology analysis it is important to analyze a relatively
large number of genes (e.g. 100 [22]) in order to avoid sto-
chastic errors, e.g. if a list of 10 genes is analyzed, the pre-
sence of a single gene (10%) of a certain class or belonging
to a certain pathway will appear overrepresented com-
pared to the prevalence in the genome, when in fact this is
just a sampling artifact. The lack of strong GO associa-
tions between the up-regulated genes in our study does
not mean that individual genes might not be strongly dys-
regulated, significant and predictive in GBM exoRNA, but
simply that the up-regulated genes do not appear to be
associated by already known relationships. Up-regulation
of specific genes in exoRNA from GBM patients could be
a biological response from normal cells to the presence of
the tumour, but they could also be specifically derived
from the tumour cells and as such be useful as markers of
the tumour. However, identifying uniquely elevated levels
of tumour-derived exoRNAs in a high background of nor-
mal exoRNA from other serum microvesicle sources is
more challenging than identifying systemic changes, such
as the depressed lymphocyte count and ribosomal protein
RNA levels.
The observation that the up-regulated genes chosen
for qRT-PCR validation was not verified may be attribu-
ted to the fact that we used two different sets of serum
samples for the microarray analysis and the qRT-PCR
validation, making borderline significant increases diffi-
cult to confirm. Similarly, the positive validation of the
down-regulated genes in a separate set of samples
makes this observation stronger.
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increased amounts of microvesicle RNA in GBM patient
serum compared to normal controls, the expression
levels of all the genes we investigated by qRT-PCR were
lower than in normal controls when normalized to total
RNA amount (Figure 5). It is likely that this is a general
trend across most mRNAs, and since all these genes are
down-regulated other transcripts must be up-regulated
to account for the overall increase in RNA amounts.
The Bioanalyzer profiles of the different RNA serum
samples suggest that this up-regulation of RNA in the
GBM patients mainly falls in the range of < 300 nt. This
could explain why the majority of the tumour exoRNA
transcripts appeared down-regulated on the array. If the
< 300 nt RNAs do not contain sequences belonging to
the coding genes, they would not have been picked up
by the microarray and the mRNA-fraction recognized
by the capture probes would be relatively smaller since
the same amount of input RNA was used for hybridiza-
tion. There are many RNA species that are not covered
by the microarray, including miRNA (mature and pre-
cursors), repetitive elements and other non-coding
RNAs, as well as single stranded DNA [28,34].
Balaj et al. [28] showed that human endogenous retro-
viruses and other transposable elements, as well as sin-
gle stranded DNA fragments are very abundant in
microvesicles from cancer cells, as compared to normal
fibroblasts, including Alu, LINE and HERV sequences
and it is likely that these and other non-coding RNAs
are contributing to the increased amounts of RNA we
observe in GBM patient serum (single stranded DNA is
also detected on the Bioanalyzer RNA chip). We tested
as i n g l et r a n s p o s a b l ee l e m e n tA l u - Yb yq R T - P C Ra n d
found it to be extremely abundant in the microvesicles,
but did not observe any differential expression between
the GBMs and normal controls. The human genome
consists of about 40% retrotransposon sequences [35],
and there is an increasing number of publications show-
ing the dysregulation of transposable elements and
other non-coding RNAs in cancer [36-38].
The very existence of the peak of < 500 nt RNAs in
GBM serum exoRNA make it a fertile ground for bio-
marker discovery, and it warrants further investigation
to establish the exact nature and distribution of the
nucleic acid species contained in this fraction. A num-
ber of regulatory non-coding RNAs are transcribed off
coding elements [39]. Collectively, down-regulation of
specific RNAs and up-regulation of RNA levels in exo-
somes/microvesicles from serum of GBM patients, as
compared to controls provides promising biomarkers. In
addition, in other studies, tumour mutant mRNAs [18]
and elevated oncogene mRNA [28] have been detected
in serum exosomes/microvesicles from human GBM
patients and mice bearing medulloblastoma tumours,
respectively. Tumour mutant RNA from prostate cancer
patients can also be found in urine exosomes/microvesi-
cles [40]. More detailed analysis of exoRNA released by
tumour cells into serum should be possible as isolation
methods are developed with tumour specific surface
markers for different types of cancer, e.g. with magnetic
activated sorting [30] and microfluidic capture [41].
Conclusions
Currently, there are no biomarkers for gliomas to distin-
guish tumor recurrence from radiation necrosis or to
monitor tumor response to therapy. Here we demon-
strate that frozen, biobanked glioblastoma serum micro-
vesicles contain RNA in amounts and qualities sufficient
to perform qPCR and microarray analysis, and we show
that glioma exoRNA profiles are unique compared to
tumor free individuals. The most significant expression
differences pertained to down-regulated genes in the
GBM patient exoRNA, which we were able to validate
by qRT-PCR. However, overall yields of exoRNA from
GBM patient serum microvesicles was higher than yields
from normal controls, but the additional RNA was pri-
marily of size < 500 nt, evident by a peak of small RNAs
on the bioanalyzer profiles. Gene ontology analysis of
the down-regulated genes indicated these are primarily
mRNAs coding for ribosomal proteins and other genes
related to ribosome production. The observation may be
explained by a reduced contribution of exoRNA from
lymphocytes, which have previously been reported to
have high expression levels of these transcripts. This
theory was supported by the lymphocyte counts in the
blood of the patients investigated in this study, which
was substantially lower than the normal reference
interval.
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